Two new studies were published late last week in JAMA Oncology on COVID-19 and cancer patients, one from Israel showing good immune response to the Pfizer/BioNTech coronavirus vaccine and one from Japan finding that cancer patients were as likely as healthcare workers (HCWs) to have serum SARS-CoV-2 antibodies.90% had immune response after 2 vaccine dosesIn the first study, a team led by researchers from Beilinson Hospital in Petah Tikva, Israel, compared SARS-CoV-2 seropositivity in 102 adult patients undergoing intravenous therapy for solid tumors at a single center with 78 healthy controls from Feb 22 to Mar 15, 2021.